复宏汉霖H药III期临床研究数据登顶《柳叶刀》与ASCO 开创胃癌围术期“去化疗”新范式

中国网财经
Jun 02

中国网财经6月2日讯复宏汉霖(2696.HK)今日宣布,公司自主研发的创新型抗PD-1单抗H药汉斯状®(斯鲁利单抗)用于胃癌新辅助/辅助治疗的III期临床研究(ASTRUM-006)数据,在2026年美国临床肿瘤学会(ASCO)年会以口头报告的形式首次正式发布,并同步在线发表于国际顶尖医学期刊《柳叶刀》,斩获国际两大顶级学术平台权威认可。  该研究由北京大学肿瘤医院季加孚教授、沈琳教授牵头。面对...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10